Lixte Biotechnology (LIXTW) Stock Price, News & Analysis

Company Overview

Lixte Biotechnology (NASDAQ:LIXTW) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapeutics for the treatment of cancer. Its lead candidate, LB-100, is a first-in-class inhibitor of protein phosphatase 2A (PP2A) that has been evaluated in early-phase clinical trials across multiple tumor types. Through strategic collaborations with academic research centers and clinical investigators, the company is exploring LB-100 both as a monotherapy and in combination regimens, including with radiotherapy and chemotherapeutic agents.

In addition to its lead program, Lixte maintains a preclinical pipeline of analogs and related compounds designed to broaden its oncology franchise. Preclinical studies aim to characterize the pharmacological profiles and therapeutic windows of these molecules, with the goal of advancing select candidates into human studies. Lixte leverages its expertise in medicinal chemistry, translational research and clinical trial design to progress its portfolio efficiently toward proof-of-concept milestones.

Founded in 2005 and headquartered in Calgary, Alberta, Canada, Lixte operates with a lean organizational structure that maximizes resource allocation toward research and development. Its clinical development efforts span North America and Europe, working with leading cancer centers to evaluate safety and efficacy endpoints. The company is led by a management team with extensive experience in oncology drug development and regulatory strategy, and it is committed to addressing unmet medical needs through innovative small-molecule therapies.

Key Stats

• Today's Range: $0.05 to $0.05
• 50-Day Range: $0.01 to $0.13
• 52-Week Range: $0.01 to $0.38
• Volume: 73,885 shs
• Average Volume: 31,625 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:LIXTW
• CIK: 1335105
• Web: lixte.com
• Phone: 631-830-7092
• Fax: N/A
• Employees: 4
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A